<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
margin-top:0cm;
margin-right:0cm;
margin-bottom:8.0pt;
margin-left:36.0pt;
line-height:105%;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
p.msolistparagraphcxspfirst, li.msolistparagraphcxspfirst, div.msolistparagraphcxspfirst
{mso-style-name:msolistparagraphcxspfirst;
margin-top:0cm;
margin-right:0cm;
margin-bottom:0cm;
margin-left:36.0pt;
margin-bottom:.0001pt;
line-height:105%;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
p.msolistparagraphcxspmiddle, li.msolistparagraphcxspmiddle, div.msolistparagraphcxspmiddle
{mso-style-name:msolistparagraphcxspmiddle;
margin-top:0cm;
margin-right:0cm;
margin-bottom:0cm;
margin-left:36.0pt;
margin-bottom:.0001pt;
line-height:105%;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
p.msolistparagraphcxsplast, li.msolistparagraphcxsplast, div.msolistparagraphcxsplast
{mso-style-name:msolistparagraphcxsplast;
margin-top:0cm;
margin-right:0cm;
margin-bottom:8.0pt;
margin-left:36.0pt;
line-height:105%;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
p.msonormal00, li.msonormal00, div.msonormal00
{mso-style-name:msonormal0;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
p.msochpdefault, li.msochpdefault, div.msochpdefault
{mso-style-name:msochpdefault;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:10.0pt;
font-family:"Times New Roman",serif;}
span.emailstyle19
{mso-style-name:emailstyle19;
font-family:"Calibri",sans-serif;
color:windowtext;}
span.emailstyle20
{mso-style-name:emailstyle20;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.emailstyle21
{mso-style-name:emailstyle21;
font-family:"Arial",sans-serif;
color:#002060;}
span.emailstyle22
{mso-style-name:emailstyle22;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.emailstyle23
{mso-style-name:emailstyle23;
font-family:"Arial",sans-serif;
color:#002060;}
span.E-MailFormatvorlage29
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.E-MailFormatvorlage30
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:70.85pt 70.85pt 2.0cm 70.85pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1027" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="DE-CH" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="color:#1F497D;mso-fareast-language:EN-US">Dear all<o:p></o:p></span></p>
<p class="MsoNormal"><span style="color:#1F497D;mso-fareast-language:EN-US"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="color:#1F497D;mso-fareast-language:EN-US">I would like to just briefly chime in to remind folks that the GAC consensus input includes a number of considerations about enforceability of PICs which go in a similar
direction…<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="color:#1F497D;mso-fareast-language:EN-US"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="color:#1F497D;mso-fareast-language:EN-US">Kindly<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="color:#1F497D;mso-fareast-language:EN-US"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="color:#1F497D;mso-fareast-language:EN-US">Jorge
<o:p></o:p></span></p>
<div>
<div>
<p class="MsoNormal"><span lang="EN-US" style="color:#1F497D"> </span><span lang="EN-US"><o:p></o:p></span></p>
<div>
<div style="border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0cm 0cm 0cm">
<p class="MsoNormal"><b><span lang="DE">Von:</span></b><span lang="DE"> Gnso-newgtld-wg <<a href="mailto:gnso-newgtld-wg-bounces@icann.org">gnso-newgtld-wg-bounces@icann.org</a>>
<b>Im Auftrag von </b>Levine, Gertrude<br>
<b>Gesendet:</b> Montag, 16. November 2020 22:34<br>
<b>An:</b> <a href="mailto:gnso-newgtld-wg@icann.org">gnso-newgtld-wg@icann.org</a>;
<a href="mailto:gnso-newgtld-wg-bounces@icann.org">gnso-newgtld-wg-bounces@icann.org</a><br>
<b>Betreff:</b> [Gnso-newgtld-wg] Proposed edits to Recommendation 9.1 re: Category 1 Safeguards</span><span lang="EN-US"><o:p></o:p></span></p>
</div>
</div>
<p class="MsoNormal"> <span lang="EN-US"><o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US">Hi all,<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US"> <o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US">In last Thursday’s SubPro meeting, we discussed Topic 9: Category 1 Safeguards – in particular, Recommendation 9.1, which reads, in part, as follows:
<b>“</b>Mandatory Public Interest Commitments (PICs) currently captured in Specification 11 3(a)-(d) of the Registry Agreement must continue to be included in Registry Agreements for gTLDs in subsequent procedures. …”<o:p></o:p></span></p>
<p class="MsoListParagraph" style="mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:72.0pt;margin-bottom:.0001pt;line-height:normal">
<b><span lang="EN-US"> </span></b><span lang="EN-US"><o:p></o:p></span></p>
<p class="MsoListParagraph" style="margin:0cm;margin-bottom:.0001pt;line-height:normal">
<span lang="EN-US">The section in question was Specification 11 3(a):<o:p></o:p></span></p>
<p class="MsoListParagraph" style="margin:0cm;margin-bottom:.0001pt;line-height:normal">
<span lang="EN-US"> <o:p></o:p></span></p>
<p class="MsoListParagraph" style="margin-bottom:0cm;margin-bottom:.0001pt;line-height:normal">
<b><span lang="EN-US">Specification 11 3(a)-(d): </span></b><span lang="EN-US"><o:p></o:p></span></p>
<p class="MsoListParagraph" style="margin-bottom:6.0pt;line-height:normal"><span lang="EN-US">3. Registry Operator agrees to perform the following specific public interest commitments, which commitments shall be enforceable by ICANN and through the Public Interest
Commitment Dispute Resolution Process . . .<o:p></o:p></span></p>
<p class="MsoListParagraph" style="margin-bottom:0cm;margin-bottom:.0001pt;line-height:normal">
<span lang="EN-US">(a) Registry Operator will include a provision in its Registry-Registrar Agreement that requires Registrars to include in their Registration Agreements a provision prohibiting Registered Name Holders from distributing malware, abusively operating
botnets, phishing, piracy, trademark or copyright infringement, fraudulent or deceptive practices, counterfeiting or otherwise engaging in activity contrary to applicable law, and providing (consistent with applicable law and any related procedures) consequences
for such activities including suspension of the domain name. <o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="color:black"> </span><span lang="EN-US"><o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="color:black">As we discussed in the meeting, Specification 11 3(a) as currently written falls short of its intended purpose, protecting end users. It is therefore necessary to revise Specification 11 3(a) to hold
new TLDs that are subject to Category 1 Safeguards accountable for their registrants’ contractual compliance with those safeguards. Existing TLDs could be grandfathered as exempt from the Specification 11 3(a) revision.</span><span lang="EN-US"><o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="color:black"> </span><span lang="EN-US"><o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="color:black">It seems there was some interest among the working group members to further explore this idea.</span><span lang="EN-US"><o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="color:black"> </span><span lang="EN-US"><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom:6.0pt"><span lang="EN-US" style="color:black">I would propose changing Recommendation 9.1 in the final report to add the underlined text below:</span><span lang="EN-US"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span lang="EN-US">“</span></b><span lang="EN-US">Mandatory Public Interest Commitments (PICs) currently captured in Specification 11 3(a)-(d) of the Registry Agreement must continue to be included in Registry Agreements for gTLDs in
subsequent procedures.” <u>In addition, Specification 11 3(a) should be revised <span style="color:black">
to hold new TLDs that are subject to Category 1 Safeguards accountable for their registrants’ contractual compliance with those safeguards. Existing TLDs could be grandfathered as exempt from the Specification 11 3(a) revision.</span></u><o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US"> <o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US">I’d be interested to hear others’ thoughts.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US"> <o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US">Thanks,<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US">Gg<o:p></o:p></span></p>
<p class="MsoNormal"><b><span lang="EN-US" style="font-size:12.0pt"> </span></b><span lang="EN-US"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span lang="EN-US" style="font-size:12.0pt">Gertrude “Gg” Levine</span></b><span lang="EN-US"><o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US">Digital Health Manager<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom:12.0pt"><span lang="EN-US">847/391-4497<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-top:18.0pt"><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
<v:stroke joinstyle="miter" />
<v:formulas>
<v:f eqn="if lineDrawn pixelLineWidth 0" />
<v:f eqn="sum @0 1 0" />
<v:f eqn="sum 0 0 @1" />
<v:f eqn="prod @2 1 2" />
<v:f eqn="prod @3 21600 pixelWidth" />
<v:f eqn="prod @3 21600 pixelHeight" />
<v:f eqn="sum @0 0 1" />
<v:f eqn="prod @6 1 2" />
<v:f eqn="prod @7 21600 pixelWidth" />
<v:f eqn="sum @8 21600 0" />
<v:f eqn="prod @7 21600 pixelHeight" />
<v:f eqn="sum @10 21600 0" />
</v:formulas>
<v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect" />
<o:lock v:ext="edit" aspectratio="t" />
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t75" alt="" style='position:absolute;margin-left:0;margin-top:0;width:77.25pt;height:86.25pt;z-index:251658240;mso-wrap-distance-left:3pt;mso-wrap-distance-top:0;mso-wrap-distance-right:3pt;mso-wrap-distance-bottom:0;mso-position-horizontal:left;mso-position-horizontal-relative:text;mso-position-vertical-relative:line' o:allowoverlap="f">
<v:imagedata src="cid:image006.png@01D6C259.8FD13A20" o:title="image002" />
<w:wrap type="square"/>
</v:shape><![endif]--><![if !vml]><img width="103" height="115" style="width:1.0694in;height:1.1944in" src="cid:image006.png@01D6C259.8FD13A20" align="left" hspace="4" v:shapes="_x0000_s1026"><![endif]><b><span lang="EN-US" style="font-size:14.0pt">National
Association of Boards of Pharmacy</span></b><span lang="EN-US"><o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="color:black">1600 Feehanville Dr, Mount Prospect, IL 60056</span><span lang="EN-US"><o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US"><a href="http://www.nabp.pharmacy/"><span style="color:blue">www.nabp.pharmacy</span></a> |
<u><a href="mailto:glevine@nabp.pharmacy">glevine@nabp.pharmacy</a></u><o:p></o:p></span></p>
<table class="MsoNormalTable" border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse">
<tbody>
<tr style="height:31.95pt">
<td width="45" style="width:34.05pt;padding:0cm 5.4pt 0cm 5.4pt;height:31.95pt">
<p class="MsoNormal"><a href="https://www.facebook.com/NABP1904/"><span style="color:windowtext;text-decoration:none"><img border="0" width="31" height="31" style="width:.3263in;height:.3263in" id="Picture_x0020_7" src="cid:image007.png@01D6C259.8FD13A20"></span></a><o:p></o:p></p>
</td>
<td width="45" style="width:34.05pt;padding:0cm 5.4pt 0cm 5.4pt;height:31.95pt">
<p class="MsoNormal"><a href="https://twitter.com/nabp"><span style="color:windowtext;text-decoration:none"><img border="0" width="31" height="31" style="width:.3263in;height:.3263in" id="Picture_x0020_8" src="cid:image008.png@01D6C259.8FD13A20"></span></a><o:p></o:p></p>
</td>
<td width="45" style="width:34.05pt;padding:0cm 5.4pt 0cm 5.4pt;height:31.95pt">
<p class="MsoNormal"><a href="https://www.linkedin.com/company/national-association-of-boards-of-pharmacy/"><span style="color:windowtext;text-decoration:none"><img border="0" width="31" height="31" style="width:.3263in;height:.3263in" id="Picture_x0020_9" src="cid:image009.png@01D6C259.8FD13A20"></span></a><o:p></o:p></p>
</td>
<td width="45" style="width:34.05pt;padding:0cm 5.4pt 0cm 5.4pt;height:31.95pt">
<p class="MsoNormal"><a href="https://www.youtube.com/c/NationalAssociationofBoardsofPharmacy"><span style="color:windowtext;text-decoration:none"><img border="0" width="31" height="31" style="width:.3263in;height:.3263in" id="Picture_x0020_10" src="cid:image010.png@01D6C259.8FD13A20"></span></a><o:p></o:p></p>
</td>
</tr>
</tbody>
</table>
<p class="MsoNormal"><span lang="EN-US"> <o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US"> <o:p></o:p></span></p>
</div>
</div>
</div>
</body>
</html>